

ESMO Immuno-Oncology Virtual Congress 2020 Industry Satellite Symposium

Perspectives on the role of circulating tumour DNA

Welcome and introduction: circulating tumour DNA and its role in the management of patients with cancer

Joaquim Bellmunt, co-chair (USA)

Current status on circulating tumour DNA and its future role in clinical practice

Jürgen Gschwend, co-chair (Germany)

Circulating tumour DNA as an emerging biomarker in urothelial cancer

Joaquim Bellmunt

Friday 11 December

17.00–18.00

Channel 1

Available on demand until 15 December 2020

(also hosted on OncologyPRO for ESMO members for 2 years)

Live panel discussion

Friday 11 December 2020, 17.45–18.00 CET

ESMO Immuno-Oncology Virtual Congress 2020 Industry Satellite Symposium

Perspectives on the role of circulating tumour DNA

Dear Colleague

We are pleased to invite you to the Roche satellite symposium **Perspectives on the role of circulating tumour DNA**.

Cancer immunotherapy, especially use of PD-L1/PD-1 inhibitors, has revolutionised the treatment landscape of many types of cancer. As only a minority of patients respond or achieve durable clinical benefit with these options, there is a need for biomarkers to identify those patients that can benefit most from treatment.

Circulating tumour DNA (ctDNA) is emerging as a potential biomarker. As well as its prognostic role, ctDNA has multiple clinical applications such as detection of minimal residual disease after surgery, monitoring treatment benefit and evaluating resistance to therapy.

During this symposium we will examine the utility of ctDNA. Firstly, we will describe the underlying rationale for ctDNA as a biomarker. Next, we will assess the most recent clinical evidence supporting use of ctDNA to manage patients with cancer. Finally, we will explore the future opportunities for ctDNA in urothelial cancer, and how ctDNA may be of particular benefit in the adjuvant setting. Finally, the topics presented during the symposium will be revisited during a live Q&A session.

We hope you will be able to join us at this highly informative and thought-provoking virtual meeting.

Dr Joaquim Bellmunt (Co-chair)

*Beth Israel Deaconess Medical Center
Boston, MA, USA*

Professor Jürgen Gschwend (Co-chair)

*Technical University of Munich
Munich, Germany*